Clinical Trial Update: Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria [NA]

View source ↗

Summary

A terminated clinical trial comparing proton radiotherapy plus sorafenib to sorafenib alone for hepatocellular carcinoma beyond the San Francisco criteria; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• proton radiotherapy

Snippet

Sponsor: Loma Linda University | Conditions: Carcinoma, Hepatocellular | NA | Status: TERMINATED | Results posted: 2021-09-22